Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2023-07-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Changes in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Daewon Pharmaceutical. It details specific transactions (gifts/transfers) of shares by major shareholders and directors. This type of filing is a standard regulatory requirement for reporting insider share movements and changes in major ownership stakes. In the provided taxonomy, this aligns with 'Director's Dealing' (DIRS) as it reports personal share transactions by company directors and executives, or 'Major Shareholding Notification' (MRQ). Given the focus on major shareholders and the specific reporting of ownership changes, 'MRQ' is the most accurate classification.
2023-07-04 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Daewon Pharmaceutical regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure, which details changes to the terms of existing financial instruments (specifically conversion prices), falls under capital structure and financing updates. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most accurate category for adjustments to convertible debt terms.
2023-05-24 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Daewon Pharmaceutical Co., Ltd. covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial statements, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과) for Daewon Pharmaceutical. It details the approval of financial statements, dividend declarations, election of directors, and other agenda items voted upon during the meeting held on March 24, 2023. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2023-03-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of board and management changes, specifically the appointment of a director.
2023-03-24 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for Daewon Pharmaceutical Co., Ltd. covering the fiscal year 2022. It contains detailed financial statements, management discussion and analysis, auditor's opinion, and corporate governance information. As it is a full-year comprehensive financial report, it is classified as an Annual Report (10-K). FY 2022
2023-03-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.